Effect of RDX-002 on Postprandial Triglycerides in Subjects Treated With Olanzapine

Clinical trial NCT05857566 · COMPLETED

Trial details

NCT number: NCT05857566
Sponsor: Response Pharmaceuticals
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Drug-induced Weight Gain

Start date: 2023-05-16
Primary completion: 2023-07-13
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.